The June 1, 2017, article by Martinelli, et al, entitled “Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study,” (J Clin Oncol 35:1795-1802, 2017), contained an error.
In the legend of table 2, last key, the “of” should be replaced with ≥. The sentence should have read as, “Complete MRD response was defined as no detectable PCR amplification of BCR-ABL1 genes (sensitivity ≥ 10-5) as assessed by a central laboratory.”
The online version has been corrected in departure from the print. The authors apologize for the error.